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Preterm birth is the leading cause of infant death worldwide, but the 
causes of preterm birth are largely unknown. During the early COVID-
19 lockdowns, dramatic reductions in preterm birth were reported; 
however, these trends may be offset by increases in stillbirth rates. It 
is important to study these trends globally as the pandemic continues, 
and to understand the underlying cause(s). Lockdowns have 
dramatically impacted maternal workload, access to healthcare, 
hygiene practices, and air pollution - all of which could impact 
perinatal outcomes and might affect pregnant women differently in 
different regions of the world. 
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In the international Perinatal Outcomes in the Pandemic (iPOP) Study, 
we will seize the unique opportunity offered by the COVID-19 
pandemic to answer urgent questions about perinatal health. In the 
first two study phases, we will use population-based aggregate data 
and standardized outcome definitions to: 1) Determine rates of 
preterm birth, low birth weight, and stillbirth and describe changes 
during lockdowns; and assess if these changes are consistent globally, 
or differ by region and income setting, 2) Determine if the magnitude 
of changes in adverse perinatal outcomes during lockdown are 
modified by regional differences in COVID-19 infection rates, 
lockdown stringency, adherence to lockdown measures, air quality, or 
other social and economic markers, obtained from publicly available 
datasets. We will undertake an interrupted time series analysis 
covering births from January 2015 through July 2020. 
The iPOP Study will involve at least 121 researchers in 37 countries, 
including obstetricians, neonatologists, epidemiologists, public health 
researchers, environmental scientists, and policymakers. We will 
leverage the most disruptive and widespread “natural experiment” of 
our lifetime to make rapid discoveries about preterm birth. Whether 
the COVID-19 pandemic is worsening or unexpectedly improving 
perinatal outcomes, our research will provide critical new information 
to shape prenatal care strategies throughout (and well beyond) the 
pandemic.
Keywords 
pandemic lockdowns, COVID-19, preterm birth, stillbirth, low birth 
weight, perinatal outcomes, global trends
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Introduction
The COVID-19 pandemic and response measures taken to 
mitigate the spread of infection have dramatically impacted 
health and health systems across the globe. Maternal and child 
health is at high risk, especially in low- and middle-income 
countries where resources for health care are already limited1. 
Pandemic response measures may have profound societal 
impacts owing to the combination of constrained supply, reduced 
resources, suppressed human interaction, and worsening 
socio-economic inequality. Projections already suggest about 
a 45% increase in child deaths and 39% increase in maternal 
deaths across low- and middle-income countries related to 
the pandemic2.
Unexpectedly, recent evidence from some high-income 
countries suggests unprecedented reductions in preterm 
births (up to 90% in Denmark and 23% in the Netherlands) 
and births classified as very low birth weight (70% in Ireland) 
following the COVID-19 lockdowns3–5. At the same time, 
reports from Nepal and India show an alarming increase in 
stillbirths and preterm births related to changes in maternity 
care6,7. Increases in stillbirth have also been seen in the UK 
and Italy (Lazio region)8,9. In California, preterm birth rates 
seem largely unchanged during the pandemic period, except 
for a modest increase (11%) in very preterm birth, driven 
primarily by the Hispanic/Latinx population10.
It is critical to evaluate these seemingly contrasting trends 
and to understand the underlying mechanisms. The pandemic 
mitigation measures have substantially impacted maternal 
workload11, access to healthcare12, hygiene practices13, air 
pollution14, nutrition15–17, and non-SARS-CoV-2 infection18, 
each of which may have affected maternal and perinatal 
outcomes disproportionately in different socio-economic and 
regional settings. It is plausible that changes in exposures to 
inflammatory triggers, such as infections19–21 and air pollution22, 
may be partly responsible for changes to some perinatal out-
comes, such as spontaneous preterm birth. We will therefore 
seize the unique opportunity resulting from the global 
COVID-19 pandemic to answer pressing questions on pandemic 
lockdowns and perinatal health on a global scale.
To address the impact of the pandemic response measures 
on perinatal health, the international Perinatal Outcomes in the 
Pandemic (iPOP) study, is working in partnership with the 
International COVID-19 Data Alliance (ICODA, supported 
by the COVID-19 Therapeutics Accelerator) to establish an 
inclusive international research programme that will collaborate 
to focus on key questions relevant to countries across the globe 
of all income levels. The initial focus of iPOP will be on the 
impact of COVID‐19 pandemic lockdowns on perinatal outcomes, 
including preterm birth, low birth weight, and stillbirth.
Objective
The overall objective of iPOP is to determine the impact of 
pandemic lockdowns on perinatal outcomes worldwide, and to 
investigate potential mechanisms underlying these effects.
Protocol
Study goals and conceptual framework
The overarching goal of iPOP is to:
•    Investigate the impact of COVID-19 lockdowns on 
perinatal outcomes (including preterm birth, low birth weight, 
and stillbirth);
•    Compare the impact of COVID-19 lockdown on perinatal 
outcomes by country income setting: low-income coun-
tries (LICs), lower-middle-income countries (LMICs), 
upper-middle-income countries (UMICs) and high-income 
countries (HICs);
•    Explore the underlying societal and etiological factors 
that are associated with between-country differences in 
the impact of COVID-19 lockdown on perinatal outcomes.
The conceptual framework (Figure 1) for the iPOP project 
is intended to help build a series of work packages (WPs), 
each increasing in complexity and building on the previous 
findings. Within this protocol we address WP1 and WP2.
WP1 - Describe global trends and regional differences in adverse 
perinatal outcomes during COVID-19 pandemic lockdowns, using 
population-based aggregate data and standardized outcome 
definitions: Report rates of preterm birth, low birth weight, and 
stillbirth and describe changes during the pandemic lockdown. 
Determine if these changes are consistent globally, or if they 
differ between or within LIC, LMIC, UMIC and HIC settings.
WP2 - Address contextual influences and mechanisms for 
changes in preterm birth, stillbirth, and low birth weight during 
the COVID-19 pandemic, using population-based aggregate and 
publicly available data: determine if the magnitude of regional 
changes in adverse perinatal outcomes during lockdown are 
potentially modified by regional differences in COVID-19 
infection rates, lockdown stringency, adherence to lockdown 
measures, air quality, and other social and economic markers 
available from public datasets.
Possible mechanisms driving the association between pandemic 
lockdown measures and perinatal outcomes are represented 
in a directed acyclic graph (DAG) in Figure 2.
Aims
In WP1, we will estimate the impact of pandemic lockdowns 
on global incidence of preterm birth, low birth weight, and 
stillbirth using population-based data. Specifically, we will 
answer the following questions:
1. Has implementation of COVID-19 pandemic lockdowns 
been associated with a change in preterm birth rate (<37 weeks 
gestation)?
2. Does the association vary:
    a)     When the outcome is restricted to spontaneous preterm 
birth (preterm birth preceded by spontaneous contractions 
and/or preterm prelabour rupture of membranes)?
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Figure 1. iPOP Study Conceptual Framework. OECD, Organisation for Economic Co-operation and Development.
Figure 2. Full directed acyclic graph (DAG) of lockdown to perinatal outcomes.
Page 6 of 16
Wellcome Open Research 2021, 6:21 Last updated: 02 JUN 2021
b)     When the outcome is restricted to early preterm birth 
(<32 weeks gestation)?
3. Does any association with preterm birth remain when 
analyses are restricted to live births only (i.e. exclusion of 
stillbirths)?
4. Has implementation of COVID-19 pandemic lockdown 
been associated with a change in low birth weight rate (<2500g)?
5. Has implementation of COVID-19 pandemic lockdown been 
associated with a change in stillbirth rate?
6. Has implementation of COVID-19 pandemic lockdown 
been associated with a change in post term birth rate (≥42 weeks 
gestation)?
7. Do any observed associations with preterm birth, low birth 
weight, and stillbirth vary by country income setting (LIC, 
LMIC, UMIC, HIC)?
Our primary hypothesis is that the rate of spontaneous 
preterm birth, low birth weight and/or stillbirth is changed 
during pandemic lockdowns worldwide. Our secondary hypoth-
esis is that the magnitude and/or direction of the change in the 
spontaneous preterm birth, low birth weight, and/or stillbirth 
varies by country income setting as classified by the World Bank 
income grouping.
In WP2 we will build directly from WP1 with the addition 
of national/regional characteristics derived from publicly 
available datasets to explore the influence of the association 
between lockdown measures and adverse perinatal outcomes.
Specifically, we will address the following questions:
8. Are the direction and magnitude of any changes in preterm 
birth, low birth weight and/or stillbirth rates observed in WP1 
modified by factors such as:
a.  Lockdown stringency index (see section Exposures 
below)
b.  Adherence to lockdown indicated by traffic and social 
mobility data
c.  Ambient air quality
d.  COVID-19 rates
e.  Parental leave policy
f.  Socioeconomic setting
g.  Gross domestic product
h.  World region (East Asia and Pacific, Europe and 
Central Asia, Latin America & the Caribbean, Middle 
East and North Africa, North America, South Asia, 
Sub-Saharan Africa).
General approach
We will analyse aggregate population-based data provided by 
collaborators from different national/regional sites. Our primary 
method of analysis will be an interrupted time series analysis 
(ITSA) and we will consider alternative quasi-experimental 
approaches as appropriate.
Results from each contributing site will be meta-analysed, 
if appropriate. We will classify data into one of three tiers 
(Standard, Enhanced, or Investigative) based on the nature 
of the datasets in terms of population coverage, quality and 
completeness, and availability of required variables (Table 1). 
Standard data meet the minimum criteria for inclusion in the 
main analysis of at least one primary or secondary outcome. 
Enhanced data meet the minimum criteria for inclusion in the 
main analysis of a primary or secondary outcome, as well as 
including additional data allowing inclusion in one or more 
additional or sensitivity analyses. Investigative data do not meet 
the minimum criteria to be included in the main analysis of a 
primary or secondary outcome but can be included in supple-
mentary analyses exploring trends (designed to promote wide 
geographical coverage).
A single contributing dataset may be categorised in different 
tiers for different analyses, e.g. a dataset with low complete-
ness on gestational age but high completeness on birth weight 
might be categorised as investigative for analyses of preterm birth 
and as enhanced for analyses of low birth weight.
Wherever possible we have aligned our definitions with those 
of the World Health Organization (WHO)23. To allow mean-
ingful comparison of international data, in our main analyses 
definitions we have used a gestational age threshold of 28 weeks, 
and birth weight threshold or 1000g for inclusion (identified 
by the extension “_m”). This is in recognition that inclusion 
of extreme preterm and extremely low birthweight births can 
disrupt the validity of such comparisons. However, these births 
will be included in definitions for the enhanced analyses (identified 
by the extension “_e”).
We have chosen to use a denominator of total births for our 
primary outcome of preterm birth. Figure 3 shows a simplified 
DAG justifying use of this denominator. COVID-19 infection 
might increase susceptibility to intrapartum stillbirth, whereas 
lockdown might reduce susceptibility to intrapartum still-
birth (because of fewer infections/ less pollution) or increase 
it (due to changes in access to maternity care). Intrapartum 
stillbirth here is a collider so we should not condition on intra-
partum stillbirth. As it is difficult to get good information on 
whether stillbirths are intrapartum (as opposed to antenatal), 
total birth is appropriate as the denominator.
Methods
Study population
Our aim is to capture, at a minimum, data on all births (live 
and stillbirth) from 28+0 to 44+6 weeks gestation inclusive; or 
above ≥1000g birth weight. We also aim to capture additional 
data on all births (live and stillbirth) from 22+0 to 27+6 weeks 
gestation, or between 500g and 999g. These data will be 
included in enhanced analyses.
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Table 1. Characteristics of datasets included in the iPOP Study.
Coverage
Standard dataset National, subnational, population-based data
Enhanced dataset National, subnational, population-based data
Investigative dataset Institutional level data or other non-population-based data
Completeness
Standard dataset ≥90% births with a meaningful/feasible value for an outcome
Enhanced dataset ≥90% births with a meaningful/feasible value for an outcome
Investigative dataset <90% births with a meaningful/feasible value for an outcome
Time period
Standard dataset 1 Jan 2015 to 31 July 2020
Enhanced dataset 1 Jan 2015 to most recent data available
Investigative dataset 1 Jan 2018 to 31 July 2020
Breakdown of data
Standard dataset By consecutive calendar month
Enhanced dataset By consecutive calendar month + by consecutive International Standard (ISO) week and 
Investigative dataset By any other time frame or discontinuous data
Birth categories
Standard dataset All births
Enhanced dataset
All births +/-
Live births and stillbirths +/-
Spontaneous preterm births
Investigative dataset
Live births only, population-based data /




28+0 - 36+6 weeks
≥37+0 weeks
Enhanced dataset
22+0 - 27+6 weeks
28+0 - 31+6 weeks
32+0 - 36+6 weeks
37+0 - 41+6 weeks
≥42+0 weeks










Investigative dataset Low birth weight identification by checkbox (without registration of birth weight)
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Figure 3. Directed acyclic graph (DAG) - Simple version (work package 1).
Study period
The main analysis study period is January 1, 2015 to July 31, 
2020, covering the first lockdown period (in 2020) and the 
previous five calendar years. We will include data from 
January 1, 2018 to July 31, 2020 in investigative analysis if 
earlier data is not available. We will request the most recent 
data available to allow enhanced analyses covering a wider 
time period.
Exposures
The primary exposure will be a binary variable for lockdown 
based on the stringency index. We will use the stringency 
index from the Oxford COVID-19 Government Response Tracker. 
The Oxford COVID-19 Government Response Tracker provides 
a systematic cross-national, cross-temporal measure to under-
stand how government responses have evolved over the full 
period of the disease’s spread. It collects information on different 
policies and interventions that governments have instituted in 
response to the COVID-19 pandemic and using standardized 
series of indicators creates a suite of composites indices to 
measure the extent of these responses. The indicators cover 
information on containment and closure policies (e.g. school 
closures and restrictions in movement) (C1-C8); economic poli-
cies (e.g. income support to citizens or provision of foreign aid) 
(E1-E4); and record health system policies (e.g. COVID-19 
testing regimes or emergency investments into healthcare) 
(H1-H5). The lockdown stringency index is calculated using 
only the policy indicators C1-C8 and H1. The value of the 
index on any given day is the average of nine sub-indices 
pertaining to the individual policy indicators, each taking 
a value between 0 and 100. If the most stringent policy is 
only present in a limited area or region, a binary flag variable 
denotes limited scope. The codebook for the stringency index is 
publicly available.
We will define lockdown as a score of ≥50 on the Oxford 
COVID-19 Government Response Tracker stringency index. 
The decision on this arbitrary cut off has been influenced by 
scoping of stringency index data in high income settings and 
comparison of stringency indexes in settings which have and 
have not implemented lockdown measures. For example, Sweden 
(which has not had a ‘lockdown’) never implemented meas-
ures during the study period that added up to higher than 50 on 
the stringency index, compared to neighbouring Denmark, 
which scored above 50 throughout the study period in 2020. 
We will record timing of reaching a score ≥50 separately for 
each country/region. Our primary analysis will focus on the 
start date of pandemic lockdown defined as the first date when a 
country/region’s stringency exceeded 49 (i.e. as a stringency 
score of ≥50).
Subsequent analyses may include the:
•    Time period of pandemic lockdown: defined as a continuous 
calendar period during which a country/region has a stringency 
score of ≥50
•    Total duration of pandemic lockdown: defined as the 
sum of all calendar periods during which a country/region 
has a stringency score of ≥50
Note: The beginning and length of lockdown may vary by 
country/region
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Comparator
Births during the 2020 lockdown periods will be compared with 
births occurring before the first date when a country/region’s 
stringency exceeded 49 (i.e. as a stringency score of ≥50), 
defined by lockdown stringency index in each country/region. 
The exact comparator time period may vary by country/region.
Outcomes
Primary outcome
•    Preterm birth rate_m (main analysis: any birth 28+0- 36+6 
weeks gestation; denominator total births ≥28+0 weeks).
•    Preterm birth rate_e (enhanced analysis: any birth 22+0- 36+6 
weeks gestation; denominator total births ≥22+0 weeks).
Secondary outcomes
•    Early preterm birth rate_m (main analysis: any birth 28+0 - 
31+6 weeks gestation; denominator total births ≥28+0 weeks).
•    Early preterm birth rate_e (enhanced analysis: any birth 
22+0 - 31+6 weeks gestation; denominator total births ≥22+0 
weeks).
•    Extreme preterm birth rate_e (enhanced analysis: any birth 
22+0 - 27+6 weeks gestation; denominator total births ≥22+0 
weeks).
•    Spontaneous preterm birth rate_e (enhanced analysis: any 
birth 28+0- 36+6 weeks gestation which is preceded by sponta-
neous contractions or preterm prelabour rupture of membranes 
[PPROM]; denominator total births ≥28+0 weeks).
•    Spontaneous preterm birth rate_e (enhanced analysis: any 
birth 22+0- 36+6 weeks gestation which is preceded by sponta-
neous contractions or preterm prelabour rupture of membranes 
[PPROM]; denominator total births ≥22+0 weeks).
•    Post term birth rate_m (main analysis: any birth ≥42+0 
weeks gestation; denominator total births ≥28+0 weeks).
•    Stillbirth rate_m (main analysis: any stillbirth ≥28+0 
weeks gestation (or ≥1000g if gestation not available); 
denominator total births ≥28+0 weeks (or ≥1000g if gestation 
not available).
•    Stillbirth rate_e (enhanced analysis: any stillbirth ≥22+0 
weeks gestation (or ≥500g if gestation not available); denomi-
nator total births ≥22+0 weeks (or ≥500g if gestation not 
available).
•    Low birth weight rate_m (main analysis: any birth 1000–2500g; 
denominator live births ≥1000g).
•    Low birth weight rate_e (enhanced analysis: any birth 
500–2500g; denominator live births ≥500g).
•    Very low birth weight rate_m (main analysis: any birth 
1000 – 1500g; denominator live births ≥1000g).
•    Very low birth weight rate_e (enhanced analysis: any 
birth 500 – 1500g; denominator live births ≥500g).
•    Extremely low birth weight rate_e (enhanced analysis: 
any birth 500g – 1000g; denominator live births ≥500g).
Potential confounders/effect modifiers
Potential confounders/effect modifiers for the entire iPOP study 
are represented in a DAG (Figure 2). We recognise that i) many 
of the variables in the DAG (e.g. maternal age distribution) are 
unlikely to have significantly changed within the timeframe 
of the analysis and thus unlikely to be confounders, and ii) our 
initial analysis strategy is to compare changes in association 
with lockdown within datasets; thus these variables are less 
relevant. To allow expedient provision and analysis of data 
we propose using aggregate data for WP1 and WP2; with 
more complex analysis enabled with provision of individual 
participant data and provider level data in subsequent WPs.
National/regional level societal characteristics that we are 
interested in exploring include mediating and moderating fac-
tors obtained from publicly available datasets as described in the 
section below. Country classification by income as defined 
by the World Bank (LIC, LMIC, UMIC, HIC) as a proxy for 
wider social security and healthcare system.
Data collection and characteristics of datasets
We have extended invitations for national, regional and 
institutional data custodians of birth data to participate through 
formal and informal networks, social media, lay and scien-
tific media. Participating countries as of December 1st 2020 are 
shown in Figure 4.
We will request aggregate data from each data provider 
using an excel spreadsheet template, which includes details 
on levels of missing data. We will classify data provided to 
iPOP as Standard, Enhanced, or Investigative, based on the 
characteristics described in Table 1.
We will also ask for completion of a questionnaire regarding 
the source of data including, country of origin, region(s) cov-
ered and size of population covered. To assist data providers 
on which template to use to capture their data, we have 
constructed a data flow diagram (Figure 5).
For WP2 we will use the following publicly available data sources:
•    Lockdown stringency: Using the stringency index (see sec-
tion Exposures) and COVID-19: Containment and Health 
Index defined as a continuous (0–100) or categorical 
measures.
•    Socioeconomic status: Measured by Organisation for 
Economic Co-operation and Development (OECD) better life 
index.
•    Ambient air quality: Estimated using the Data Integra-
tion Model for Air Quality (DIMAQ)24, which uses input 
data from a variety of public sources including: Open Air 
Quality, NASA Modern-Era Retrospective analysis for Research 
and Applications version 2 (MERRA-2) global modelling 
initiative, satellite imagery data from the Multiangle Imple-
mentation of Atmospheric Correction (MAIAC), and global 
population density from the NASA/Columbia University 
Socioeconomic Data and Applications Center.
•    Adherence to lockdown indicated by traffic and movement 
trends: Obtained from publicly available Google mobility data.
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Figure 4. Map of iPOP collaborating countries as of Dec 1, 2020.
Figure 5. Data request flow diagram.
•    COVID-19 rates: Nationally available via John Hopkins 
COVID-19 infection rates
•    Parental leave policy: Measured by World Bank Data 
(yes/no; length of paid maternity leave).
•    Other country-level characteristics: Measured by World 
Bank Data (including variables such as world region, GDP, 
income expenditure, hospital beds, maternal education), The 
Global Gender Gap Index, The Global  Hunger Index and 
Political stability index.
Data storage and analysis platform
We will use the Secure Anonymised Information Linkage (SAIL) 
Databank, Swansea Wales, to store all data provided to iPOP. 
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Upon completion of a Data Contribution Agreement between 
each iPOP data provider and the SAIL Databank, each data 
providers will either:
i)  upload aggregated data directly to the SAIL central 
repository, or
ii)  transfer their data to the University of Edinburgh 
(RM), who will upload these to SAIL on their behalf.
Data will be transferred into SAIL using the “Split-file” proc-
ess with the support of the Informatics Service, National Health 
Services (NHS) of Wales. Person-level demographics are 
translated to an Anonymous Linking Field (ALF). Additional 
information on the SAIL File Structure & Data Transfer 
processes can be found here.
iPOP Team Members (analysis team) will access data stored 
within SAIL via a remote access and conduct data analyses 
remotely on the International COVID-19 Data Alliance (ICODA) 
Workbench, via a federated approach. ICODA is a new data 
platform that allows scientists and researchers across the globe 
to discover, access and analyse multi-dimensional datasets in a 
confidential and secure environment. More information can be 
found on the HDR UK website.
To ensure outputs are confidential and safe, all statistical 
outputs will be checked using Statistical Disclosure Control 
(SDC) procedures before being exported out of the virtual 
environment. We will use SDC guiding principles from the 
Handbook on SDC for Outputs by the UK Data Service. This 
will prevent the identity of a birth from being revealed or inferred 
from outputs.
A catalogue on the data variables captured will be recorded 
alongside relevant metadata. These high-level summaries will 
be made publicly available.
Data analysis
All analyses will be fully specified in a comprehensive 
Statistical Analysis Plan. We will adhere to relevant reporting 
guidance for example the Strengthening the Reporting of 
Observational studies in Epidemiology (STROBE).
Descriptive analysis
We will use summary statistics and data visualisations to 
describe, explore and compare the national/regional data to 
describe the study outcomes and other perinatal characteristics, 
including: 
•    All births
•    Live and stillbirths
•    Preterm and post term births
•    Low birth weight
•    Spontaneous preterm births
In WP2 we will use summary statistics and data visualisations 
(e.g. choropleth maps) to describe, explore and compare the 
national/regional data.
Statistical modelling
We will undertake population-based ITSA for main analyses 
of primary and secondary outcomes. We will use time-series 
techniques to capture any underlying temporal trends and 
seasonality in the data before the implementation of lockdown 
measures. We will consider both linear and more flexible trends. 
We will use these time-series regression models to forecast (or 
predict) the expected trends and will compare these to the 
observed trends seen after the lockdown measures. This will cap-
ture both immediate (i.e. step) changes and gradual (i.e. slope) 
changes in the outcome in relation to implementation of lockdown 
measures in our models. All analyses will be prespecified in a 
Statistical Analyses Plan before analysis.
Meta-analysis
We will undertake a meta-analysis of national/regional results, 
on the step-change and the difference between the fore-
cast and observed outcomes at different time points after the 
implementation of lockdown measures. We will also stratify 
by country income setting as a dichotomous variable (LIC+LMIC 
vs UMIC+HIC), since existing data suggests differing effects 
in these groups. Statistical heterogeneity will be assessed using 
I2 test.
For WP2, we will use these pooled estimates from WP1 in 
meta-regression analyses. These will incorporate the moderator/
mediator variables as potential mechanisms at a national/regional 
level. This will measure the influence of these mechanisms on 
the association between lockdown measures and adverse perinatal 
outcomes.
Sensitivity analyses
Where enhanced datasets are available for an outcome, we will 
perform similar modelling techniques to those described above 
with these enhanced data as sensitivity analyses to test the 
robustness of the main analyses in different populations. These 
analyses will be specified further in a comprehensive Statistical 
Analysis Plan. Predefined examples include:
•    Sensitivity analyses restricting the denominator for 
our main outcomes of interest (excluding outcomes on 
spontaneous preterm birth) from all births to only live births. 
These analyses will be informative for the appropriate-
ness of using datasets which only include information on live 
births.
•    Sensitivity analyses with varying cut-off points for our 
lockdown definition (i.e. above and below 50) from the 
stringency index to test the robustness of assigning 
≥50 as the primary cut-off point. These analyses will also 
allow inclusion of countries with less strict lockdown 
measures, such as Sweden, and inform whether/to what extent 
the observed associations might vary by lockdown stringency.
We will conduct supplementary analyses in investigative datasets.
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Output confidentiality
All outputs will be checked for any potential disclosure and 
confidentiality breaches, using guidance from the Handbook on 
SDC for Outputs by the UK Data Service.
Public and patient involvement
Public and patient involvement early in study design and 
development ensures research studies are responsive to input, 
guidance and advice, and can help identify and mitigate poten-
tial challenges early in the research process25. Further, public and 
patient involvement helps to identify research outcomes that are 
meaningful and pragmatic to knowledge users.
The iPOP team has engaged parents as patient partners early 
in the study design and have built a working group to capture 
and integrate patient involvement in the iPOP study as it moves 
forward. Meeting monthly, patient partners will be involved 
in developing effective and meaningful knowledge translation 
and communication strategies for disseminating iPOP find-
ings. Specific to WP2, patient partners will work with research-
ers to examine mechanistic effects of the pandemic lockdown 
on perinatal outcomes. Patient partners will also work with 
researchers to develop knowledge translation strategies to 
ensure effective and meaningful dissemination of findings to 
knowledge users.
Ethical considerations
To ensure transparent, equitable, and meaningful engagement, 
we have developed Guiding Principles that outline the terms of 
agreement for study leads and collaborators who are involved 
in the iPOP Study. Each member of the iPOP Study must read 
and sign the guiding principles document in order to collaborate 
on the study. While not legally binding, this document provides 
guidance and parameters around authorship, roles and 
responsibilities, research integrity, communication and Team 
Science guidelines.
The iPOP Study ensures confidentiality and security of the 
processing of data for electronic files. Data will be safeguarded 
by an appropriate level of security, technical and organisational 
measures to prevent unauthorized disclosure or access, acci-
dental or unlawful destruction, accidental loss or alteration, and 
unlawful forms of processing. WP1 and WP2 will be based on 
de-identified aggregate data only.
It will be assumed that any Team member sharing data within 
the iPOP Study does so in accordance with relevant and 
applicable legal and regulatory standards and obligations includ-
ing but not limited to, confidentiality, data protection and 
intellectual property, and access governance agreements. iPOP 
collaborators must adhere to these policies and processes.
All collaborators must respect the iPOP principles of data 
protection and processing, which include the following:
All contributed to iPOP data must be
•    Processed fairly and lawfully
•    Collected for specified and legitimate purposes
•    Adequate, relevant and not excessive in relation to the 
purpose
•    Accurate
•    Absent of personal identifiers (names, addresses, etc.)
•    Stored not longer than necessary
•    Processed under the responsibility and liability of the 
data Controller for the provided data set
•    Handled according to the EU GDPR rules (when hosted 
in the UK)
Conclusions
Spanning 37 countries (Figure 4), the iPOP Study brings 
together expertise in perinatology, epidemiology, environmen-
tal science, intersectional feminism, and data science within a 
collaborative, equitable and interdisciplinary framework. 
The iPOP Study will leverage the natural experiment arising 
from the COVID-19 pandemic, to understand possible mecha-
nisms of adverse perinatal outcomes and inform interventions and 
policy. Further, iPOP will investigate the effects of pandemic 
lockdowns by country income setting, incorporating data from 
LICs to HICs across the globe on key perinatal outcomes.
The initial focus of iPOP will be on the impact of COVID-19 
pandemic lockdowns on perinatal outcomes, including pre-
term birth, low birth weight, and stillbirth. Determining the 
worldwide extent of changes in perinatal outcomes during the 
COVID-19 pandemic will advance current understanding of 
preventable causes of these pervasive perinatal outcomes.
Building on the first two phases of the iPOP Study described 
in this protocol, iPOP further aims to investigate mechanisms 
for any observed changes in perinatal outcomes during the 
COVID-19 pandemic, using individual-level and setting-specific 
data. In the next study phase (WP3), we aim to examine the 
impact of maternal comorbidities (e.g. pregnancy complica-
tions; pre-existing chronic conditions including mental health), 
COVID-19 and non-COVID-19 infections, socio-economic 
factors, prenatal care, and birth practices on any associations 
between pandemic lockdowns and perinatal outcomes.
Results of the iPOP Study will be rapidly translated through 
our network of local and international stakeholders to inform 
further research and testable interventions for improving 
perinatal healthcare and social support systems during (and well 
beyond) the COVID-19 pandemic.
Data availability
No data are associated with this article.
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Thank you for the opportunity to review this study protocol. The investigators propose a 5-year 
multi-country study to assess the impact of the COVID-19 pandemic on perinatal outcomes, 
including rates of preterm birth, low birth weight, and stillbirths, using an interrupted time series 
analysis approach. The study design is appropriate for the described research questions, and the 
investigators clearly articulate their intended methodological approach. It may be difficult to 
assess the impact of the implementation of COVID-19 related lockdowns versus the impact of the 
pandemic (and infection in pregnancy) itself. I agree with the investigators’ decision to focus on 
gestational age 28+ weeks given the heterogeneity of international data and approaches to 
classifying viability; the impact of the pandemic/lockdowns on earlier gestational ages will be 
assessed in a separate analysis (enhanced analysis as described). Classifying stillbirth may be 
challenging, given the differences in definitions and reporting internationally. 
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○




Last paragraph of introduction (page 5): Please change “COVID 19” to “COVID-19” in second 
to last line of the paragraph. 
 
○
Figure 1 (page 6): Change “birthweight” to “birth weight” to match remainder of manuscript. 
 
○
Figure 2 (page 6): Change “birthweight” to “birth weight” to match remainder of manuscript. 
Font size is quite small, making DAG difficult to read. If possible, resize figure to fit width of 
page and increase font size. Current DAG only lists limited number of confounders, though 
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many more could be explored. 
 
Figure 3 (page 3): Stillbirths are by definition always antenatal – consider using 
“antepartum” to distinguish from “intrapartum” instead. Strict classification of ante- versus 
intrapartum stillbirth may be difficult, depending on data sources. 
 
○
Outcomes (page 10): Current birth weight categories and numerators/denominators do not 
quite make sense. Would follow standard WHO or VON categories for defining and 
calculating these. What about neonates with birth weight less than 500g? Growth-restricted 
neonates may weigh less than 500 grams but still survive. 
 
○
Figure 5: Change “birthweight” to “birth weight” to match remainder of manuscript.○
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